title: [Allergic rhinitis and asthma: pathophysiological relationship and implications for treatment].
abstract: Allergic rhinitis and asthma share various clinical, pathophysiological and immunological characteristics and often coexist. Recent studies provide evidence of cross-talk between both airway compartments, possibly by systemic signalling. These observations resulted in the concept of 'allergic airway disease', providing a rationale for systemic treatment. Presently, many novel systemic treatment modalities, including anti-IgE and phosphodiesterase-4 (PDE4) inhibitors, are being evaluated in clinical trials. In the Netherlands, there are currently two registered systemic therapies targeting the pathophysiological mechanisms of the united airway disease: leukotriene receptor antagonists and immunotherapy. These therapies are usually prescribed in combination with the standard pharmacotherapy.
authors.affiliation: Centre for Human DrugResearch, afd. Long-en Allergieresearch, Zernikedreef 10, 2333 CL Leiden. z.diamant@gems.demon.nl
authors.forename: Z
authors.initials: Z
authors.lastname: Diamant
authors.forename: S
authors.initials: S
authors.lastname: Tarasevych
authors.forename: P
authors.initials: P
authors.lastname: Chandoesing
authors.forename: R Gerth
authors.initials: RG
authors.lastname: van Wijk
authors.forename: H
authors.initials: H
authors.lastname: de Groot
mesh_terms: D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D007167:Immunotherapy; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D020024:Leukotriene Antagonists